Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tiersten

Showing results (81-90 of 89) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 89 results.
Breast Cancer Research : BCR|April 2, 2014
Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancerJasmeet Singh, Yelena Novik, Stacey Stein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2012
Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancerSylvia Adams, Lina Kozhaya, Frank Martiniuk, et al.
Annals of Surgical Oncology|April 4, 2021
Association of Insulin Resistance and Higher Oncotype DX™ Recurrence ScoreNicole T Gordon, Jaime J Alberty-Oller, Kezhen Fei, et al.
Breast Cancer Research and Treatment|August 16, 2025
Randomized phase II comparison of single-agent carboplatin versus combination of carboplatin and everolimus for advanced triple negative breast cancerRima Patel, Jami Fukui, Paula Klein, et al.
Breast Cancer Research and Treatment|June 25, 2021
Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancerMatthew Kearney, Lauren Franks, Shing Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2025
A Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of a Folate Receptor Alpha Vaccine in Patients with Triple-Negative Breast CancerKeith L Knutson, Hala Abu-Fares, Patricia Keating, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2023
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN TrialKevin Kalinsky, Melissa K Accordino, Codruta Chiuzan, et al.
JAMA Oncology|January 18, 2024
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical TrialCynthia X Ma, Vera J Suman, Souzan Sanati, et al.
Cancer Discovery|March 17, 2025
PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant SettingMansi Saxena, Thomas U Marron, Julia Kodysh, et al.
Pageof 9

Showing results (81-90 of 89) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 89 results.
Breast Cancer Research : BCR|April 2, 2014
Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancerJasmeet Singh, Yelena Novik, Stacey Stein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2012
Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancerSylvia Adams, Lina Kozhaya, Frank Martiniuk, et al.
Annals of Surgical Oncology|April 4, 2021
Association of Insulin Resistance and Higher Oncotype DX™ Recurrence ScoreNicole T Gordon, Jaime J Alberty-Oller, Kezhen Fei, et al.
Breast Cancer Research and Treatment|August 16, 2025
Randomized phase II comparison of single-agent carboplatin versus combination of carboplatin and everolimus for advanced triple negative breast cancerRima Patel, Jami Fukui, Paula Klein, et al.
Breast Cancer Research and Treatment|June 25, 2021
Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancerMatthew Kearney, Lauren Franks, Shing Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2025
A Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of a Folate Receptor Alpha Vaccine in Patients with Triple-Negative Breast CancerKeith L Knutson, Hala Abu-Fares, Patricia Keating, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2023
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN TrialKevin Kalinsky, Melissa K Accordino, Codruta Chiuzan, et al.
JAMA Oncology|January 18, 2024
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical TrialCynthia X Ma, Vera J Suman, Souzan Sanati, et al.
Cancer Discovery|March 17, 2025
PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant SettingMansi Saxena, Thomas U Marron, Julia Kodysh, et al.
Pageof 9